Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New ovarian cancer hope for women

25.06.2003


Scientists bring early detection closer



Scientists at the Pacific Northwest Research Institute (PNRI) in Seattle announced a new biomarker for ovarian cancer today. Their discovery promises improved diagnosis of the disease, which usually remains hidden until it is too late for effective treatment.

In the July 1 issue of Cancer Research, the researchers describe a molecule, HE4, associated with ovarian cancer cells. Because the molecule is secreted readily into the blood, its presence should be detectable when simple and inexpensive clinical blood tests are developed.


"Many cancers have a high cure rate if diagnosed early," Dr. Ingegerd Hellstrom, a principal scientist at PNRI and the lead author of the new paper, says. "But not if diagnosed late. Unfortunately, ovarian carcinoma is most often diagnosed when it is already in an advanced stage. Even after surgery and chemotherapy, relapses are common."

According to the American Cancer Society, the survival statistics are dismal. Three out of four cases of ovarian cancer are diagnosed in late stages. Last year alone, nearly 14,000 women died of the disease.

The best currently available diagnostic test for ovarian cancer is CA125. It is useful in diagnosing late stage cancers, and in detecting the recurrence of tumors after chemotherapy and radiation. But it is not very effective in identifying early stage disease. It also sometimes indicates the presence of ovarian cancer where there is none. Such "false positive" results lead to dangerous, expensive, and unnecessary treatment.

In the Cancer Research study, the new biomarker, HE4, proved to be at least as effective as CA125. And where no false positive results occurred, HE4’s sensitivity to ovarian carcinoma was 40% higher than that of CA125.

"I’m very anxious to do something for patients," Hellstrom says. But there is much work to be done, laboratory studies with larger numbers of serum samples, and commercial development to design effective clinical applications of the research. The possibility that a simple and inexpensive blood test can be developed for clinical use is already being studied in a licensing agreement with Fujirebio Diagnostics Incorporated, the creator of CA125.

"Still, this is a step in the right direction," Hellstrom says. "And we are working as passionately and creatively as we can, to curtail this terrible disease."

Rich Murphy | EurekAlert!
Further information:
http://www.pnri.org/

More articles from Health and Medicine:

nachricht A new approach to targeting cancer cells
20.05.2019 | University of California - Riverside

nachricht Radioisotope couple for tumor diagnosis and therapy
14.05.2019 | Kanazawa University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

A simple, yet versatile, new design for chaotic oscillating circuitry inspired by prime numbers

22.05.2019 | Power and Electrical Engineering

Synthesis of helical ladder polymers

21.05.2019 | Materials Sciences

Ultra-thin superlattices from gold nanoparticles for nanophotonics

21.05.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>